volume 15 | number 11 | november 2009 nature medicine l e t t e r s Reversible methylation of histone tails serves as either a positive signal recognized by transcriptional assemblies or a negative signal that result in repression 1-4 . Invading viral pathogens that depend upon the host cell's transcriptional apparatus are also subject to the regulatory impact of chromatin assembly and modifications 5-8 . Here we show that infection by the -herpesviruses, herpes simplex virus (HSV) and varicella zoster virus (VZV), results in the rapid accumulation of chromatin bearing repressive histone H3 Lys9 methylation. To enable expression of viral immediate early (IE) genes, both viruses use the cellular transcriptional coactivator host cell factor-1 (HCF-1) to recruit the lysine-specific demethylase-1 (LSD1) to the viral immediate early promoters. Depletion of LSD1 or inhibition of its activity with monoamine oxidase inhibitors (MAOIs) results in the accumulation of repressive chromatin and a block to viral gene expression. As HCF-1 is a component of the Set1 and MLL1 histone H3 Lys4 methyltransferase complexes 9,10 , it thus coordinates modulation of repressive H3 Lys9 methylation levels with addition of activating H3 Lys4 trimethylation marks. Strikingly, MAOIs also block the reactivation of HSV from latency in sensory neurons, indicating that the HCF-1 complex is a crucial component of the reactivation mechanism. The results support pharmaceutical control of histone modifying enzymes as a strategy for controlling herpesvirus infections.
The cellular transcriptional coactivator HCF-1 is essential for expression of the IE genes of the α-herpesviruses HSV and VZV 11 . Both viruses use virion-encapsidated activators to recruit HCF-1-Set1 or HCF-1-MLL1 histone methyltransferase (HMT) complexes 9, 12 to the IE promoters, resulting in histone H3 Lys4 (H3K4) trimethylation and initiation of gene transcription 12, 13 . HCF-1 depletion results in increased levels of repressive histone H3 Lys9 (H3K9) methylation, suggesting a central role for HCF-1 in modulating chromatin modifications that determine viral gene expression.
To investigate histone methylation in herpesvirus gene expression, we assessed the state of H3K4 and H3K9 methylation by chromatin immunoprecipitation (ChIP) assays using a model VZV IE promoter-reporter. In the absence of the VZV IE activator (IE62), repressive H3K9 methylation accumulated on the promoter, whereas in its presence H3K9 methylation was reduced and positive H3K4 trimethylation was enhanced (Fig. 1a) . This indicated that, in addition to the Set1 or MLL1 H3K4 methyltransferase, an H3K9 demethylase would also be required to modulate the amounts of repressive chromatin.
Recently it has been shown that the H3K9 demethylase activity of LSD1 is crucial for nuclear hormone receptor-dependent transcription [14] [15] [16] and cell fate determination 17 . Therefore, we investigated the role of this enzyme in viral IE transcription. LSD1 occupied the VZV IE promoter-reporter with HCF-1 and Set1 in the presence but not in the absence of the viral activator ( Fig. 1b) . Furthermore, depletion of LSD1 resulted in reduced induction of the reporter, indicating that LSD1 has a role in IE62-mediated activation (Fig. 1c) .
We next asked whether LSD1 recruitment is dependent upon the coactivator HCF-1. In cells depleted of HCF-1, Set1 and LSD1 occupancy was lower and correlated with a reduction in H3K4 trimethylation and an enhancement of H3K9 methylation (eight-to ninefold; Fig. 1d ). In contrast, occupancy of the activator IE62 was not affected (Fig. 1d) .
The α-herpesviruses VZV and HSV-1 share similar regulatory mechanisms, including the recruitment of HCF-1 by the respective viral IE activators 11 . LSD1 depletion also reduced the virally induced expression of an HSV IE reporter ( Fig. 1e) . Additionally, exogenous expression of wild-type LSD1 stimulated the reporter expression (P < 0.0001), whereas a catalytic mutant had no significant impact (P = 0.2471, Fig. 1f ).
To investigate the role of these factors during viral infection, we infected HCF-1-depleted cells with VZV. In nondepleted cells, promoter occupancy by Set1, MLL1 and LSD1 was substantial, with a high level of H3K4 trimethylation and near background level of H3K9 methylation ( Fig. 2a) . In contrast, promoter occupancy by Set1, MLL1 and LSD1 was lower in HCF-1-depleted cells, with a correlating decrease in H3K4 trimethylation and increase in repressive H3K9 methylation ( Fig. 2b) . We addressed the requirement for LSD1 by infection of an inducible LSD1-RNAi cell line. Depletion of 60% of the cellular LSD1 lowered the amounts of the IE protein by 66% and mRNA by 78% ( Fig. 2c) , indicating that LSD1 is crucial for IE gene expression during viral infection.
l e t t e r s
In an analogous manner, HCF-1 and LSD1 occupied the HSV-1 IE promoter during infection, with the correlating high level of H3K4 and low level of H3K9 methylation (Fig. 2d) . Furthermore, HCF-1 depletion resulted in a concomitant decrease in the recruitment of LSD1 ( Fig. 2e) . Notably, depletion of LSD1 resulted in lower amounts of viral IE proteins and mRNAs (Fig. 2f) , and the levels of IE gene expression were recovered by exogenous expression of wild-type LSD1 but not an LSD1 catalytic mutant or a mutant lacking the amine oxidase domain ( Fig. 2g) . Strikingly, depletion of LSD1 resulted in accumulation of nucleosomes bearing repressive H3K9 methylation on the viral IE promoter ( Fig. 2h) . Together, these results demonstrate that the HCF-1-dependent recruitment of LSD1 plays a major part in the initiation of both VZV and HSV-1 infection, probably via modulation of the levels of repressive H3K9 chromatin marks at the IE promoters.
Recruitment of LSD1 is dependent on HCF-1 ( Figs. 1d and 2b,e ). Therefore, we determined whether this reflects an interaction between the two by coimmunoprecipitation assays. Both Set1-and LSD1-specific antibodies efficiently immunoprecipitated HCF-1 (Fig. 2i ). In addition, immunoprecipitation of either HCF-1 or LSD1 resulted in coimmunoprecipitation of retinoblastoma binding protein-5 (RbBP5) (Fig. 2i) , a common core subunit of the Set1 and MLL1 HMTs 18 , suggesting that LSD1 is associated with the HCF-1-HMT complex.
LSD1 has both repressive (H3K4 demethylation) and activating (H3K9 demethylation) activities. Demethylation of H3K4 is mediated by the REST co-repressor-1 (CoREST)-LSD1 complex, and targeting or specificity is determined by the associated components 19, 20 . CoREST factors were present in the LSD1 immunoprecipitate but absent from the HCF-1-LSD1 complex (Supplementary Fig. 1 ). On the basis of these data, we propose that HCF-1 couples the demethylase LSD1 with the Set1 or MLL1 HMT in a previously undescribed complex, providing both specificities to promote IE gene transcription ( Fig. 2j) .
Mechanistically, LSD1 is unique relative to other identified demethylases, including the members of the Jmjd (jumonji domain) family, as it demethylates lysine residues via a flavin-adenine dinucleotide-dependent reaction 21, 22 . This reaction is inhibited by MAOIs 15,23-25 , pharmaceuticals used in the treatment of psychiatric disorders (clinical depression and anxiety), Parkinson's disease and migraines. Furthermore, certain MAOIs inhibit LSD1 at levels comparable to their inhibition of the clinical mitochondrial MAO targets 23, 24 . Therefore, we investigated the impact of the MAOIs pargyline and tranylcypromine on the initiation of VZV and HSV infection. For both viruses, treatment with either MAOI resulted in a dose-dependent decrease in viral IE mRNA and proteins ( Fig. 3a-c) . The amounts of cellular protein controls were unaffected, and we did not observe substantial cellular toxicity ( Supplementary Fig. 2 ). Tranylcypromine also lowered viral yields from HSV-infected cells by nearly three orders of magnitude ( Fig. 3d) . Notably, analogous to RNAi-mediated LSD1 depletion ( Fig. 2h) , nucleosomes bearing repressive marks accumulated on the HSV-1 IE promoter in the presence of either MAOI (Fig. 3e) . The results support the model in which LSD1 prevents accumulation of H3K9 methylation, thereby allowing productive infection by both α-herpesviruses.
In addition to increasing mono-and dimethylation of H3K9, inhibition of LSD1 resulted in increased H3K9-trimethylation and occupancy by the heterochromatin protein 1 ( Supplementary  Fig. 3a) . As LSD1 only removes mono-and dimethyl modifications, the increased H3K9 trimethylation in the absence of LSD1 may reflect either increased levels of dimethyl substrates that accumulate during chromatin assembly or a requirement for an additional H3K9 demethylase(s) of the Jmjd family, in conjunction with LSD1, to provide the specificity required to remove trimethylation 26, 27 . The latter is supported by our observation that, even in the presence of LSD1, H3K9 trimethylation was present on the IE promoters during the initial stages of HSV-1 infection (Supplementary Fig. 3b ). Regardless, IgG l e t t e r s the requirement for LSD1 to promote viral IE expression identifies it as an essential control component and a target for inhibition of α-herpesvirus infection.
In addition to replicating lytically, α-herpesviruses establish latent infections and cycles of reactivation in sensory neurons. For HSV-1, latency and reactivation correlate with alterations in chromatin modifications on the viral IE promoters 5,28-31 . Of note, HCF-1 is sequestered in the cytoplasm of unstimulated sensory neurons, rapidly transported to the nucleus upon reactivation stimuli 32, 33 and recruited to the viral IE promoters at the outset of reactivation 34 . Therefore, given the impact of LSD1 on viral IE gene expression and its association with HCF-1, we investigated the potential role of LSD1 in viral reactivation by tissue explant of trigeminal ganglia latently infected with HSV in the presence and absence of tranylcypromine. Strikingly, tranylcypromine significantly reduced the reactivation of HSV-1 (P = 0.0043 and 0.0011 for days 2 and 4, respectively; Fig. 4a ). Owing to potential variance in viral loads of individual mice, we confirmed these results by studies in which we explanted each half of a trigeminal ganglion in the presence and absence of tranylcypromine (P = 0.0002; Fig. 4b ). Moreover, reduced levels of the inhibitor also effectively blocked viral reactivation (Fig. 4c) . Finally, potential tranylcypromine toxicity was not responsible for the suppression of viral reactivation, as we recovered high viral titers after drug reversal (Fig. 4d) .
These studies suggested that MAOI inhibition of LSD1 prevents viral reactivation. However, it remained possible that tranylcypromine inhibited lytic spread of the virus but not the initiating reactivation events. Therefore, we explanted ganglia in the presence of DMSO (control), acyclovir (to prevent viral DNA replication and spread 35, 36 ) or tranylcypromine. We probed sections with antibodies to an HSV lytic antigen (ICP8) ( Fig. 4e and Supplementary Fig. 4a) . In controltreated ganglia, clusters of ICP8 + neurons were detectable in multiple sections of 13 of 16 ganglia, representing initiating neurons as well as infected neurons and support cells from lytic spread. In the presence of acyclovir (acyclovir), we found distinct ICP8 + neurons in sections of nine of 12 ganglia, representing primary neurons undergoing viral reactivation. Notably, in the presence of tranylcypromine, we saw only a single ICP8 + neuron in one of 15 ganglia, clearly demonstrating that tranylcypromine inhibited the initiation of reactivation rather than inhibiting lytic spread (P = 0.00002) ( Fig. 4e and Supplementary  Fig. 4a ). As additional evidence that tranylcypromine inhibits IE gene expression and, consequently, reactivation of HSV from latency, viral IE mRNAs were readily detected by nested RT-PCR from ganglia explanted in the presence of DMSO or acyclovir but not in the presence of tranylcypromine ( Fig. 4f and Supplementary Fig. 4c) .
Together, these data support the model (Fig. 4g) whereby the genomes of infecting α-herpesviruses are subject to cell-directed It should be noted that the encapsidated HSV-1 genome is devoid of nucleosomes, which are deposited during the initial stage of infection 37, 38 . As positive chromatin marks are installed and viral gene transcription is activated, the levels of associated nucleosomes decrease, probably owing to targeted chromatin remodeling. In contrast, inhibition of the HCF-1 complex components results in accumulation of nucleosomes bearing H3K9 methylation and repression of viral gene expression. As LSD1 can demethylate both H3K4 and H3K9, the coupling of this protein in the HCF-1 Set1 or MLL methyltransferase complex may enhance H3K9 demethylation or preferentially target it to this substrate, although additional histone modifications and modification activities may also contribute to the H3K4 or H3K9 recognition and specificity. Moreover, the presence of the Set1 or MLL1 H3K4 methyltransferase components in the complex could function to maintain the levels of H3K4 methylation, even in the presence of LSD1 H3K4 demethylase activity.
The recruitment of HCF-1 complex during the initiation of infection emphasizes the mechanism by which these viruses escape the host cell-directed assembly of repressive chromatin. Of note, LSD1 has also recently been shown to demethylate nonhistone proteins 39, 40 , raising the possibility that components involved in the viral IE gene transcription machinery may also be modulated by LSD1-dependent demethylation.
With respect to the cycle of latency and reactivation established by these viruses, signals that lead to viral reactivation result in rapid nuclear transport 32, 33 and occupancy of viral IE promoters by HCF-1 (ref. 34) . Coupled with the data presented here that inhibition of the HCF-1-associated demethylase LSD1 blocks viral reactivation, the observations strongly support the model that HCF-1 modification complexes have a crucial role in determining the latency-reactivation state of these viruses.
The dependence of viral pathogens on host cell chromatin machinery highlights a potential for therapeutic intervention. As LSD1 is a well-defined target of MAOIs, and these pharmaceuticals are widely used therapeutically, these observations identify a new therapeutic target for herpesvirus infections and enhances the importance of ongoing efforts to develop additional LSD1 inhibitors.
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